Erythropoietin/EPO Antibody [Unconjugated]

Recombinant Human Erythropoietin/EPO (Tissue Culture Grade) (Catalog # 287-TC) stimulates proliferation in theTF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by Recombinant Human Erythropoietin/EPO (Tissue Culture Grade) (0.2 units/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Human Erythropoietin/EPO Polyclonal Antibody (Catalog # AB-286-NA). The ND50 is typically VC003). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to convoluted tubules. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: LYOPH

Erythropoietin/EPO Antibody [Unconjugated] Summary

• Immunogen: Chinese hamster ovary cell line (CHO)-derived recombinant human Erythropoietin/EPO
• Specificity: Detects human Erythropoietin/EPO in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: EPO
• Purity Statement: Protein A or G purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization <3 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 1 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Erythropoietin/EPO Antibody [Unconjugated]

• ECYT5
• EP
• EPO
• epoetin
• Erythropoietin
• MGC138142
• MVCD2

Background

Erythropoietin (EPO) is a 34 kDa glycoprotein hormone in the type I cytokine family and is related to thrombopoietin. Its three N-glycosylation sites, four alpha helices, and N- to C-terminal disulfide bond are conserved across species. Glycosylation of EPO is required for biological activities in vivo. Mature human EPO shares 75%‑84% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat EPO. Epo is primarily produced in the kidney by a population of fibroblast-like cortical interstitial cells adjacent to the proximal tubules. It is also produced in much lower, but functionally significant amounts by fetal hepatocytes and in adult liver and brain. EPO promotes erythrocyte formation by preventing the apoptosis of early erythroid precursors which express the EPO receptor (EPO R). EPO R has also been described in brain, retina, heart, skeletal muscle, kidney, endothelial cells, and a variety of tumor cells. Ligand induced dimerization of EPO R triggers JAK2-mediated signaling pathways followed by receptor/ligand endocytosis and degradation. Rapid regulation of circulating EPO allows tight control of erythrocyte production and hemoglobin concentrations. Anemia or other causes of low tissue oxygen tension induce EPO production by stabilizing the hypoxia-induceable transcription factors HIF-1 alpha and HIF-2 alpha . EPO additionally plays a tissue-protective role in ischemia by blocking apoptosis and inducing angiogenesis.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Erythropoietin/EPO Antibody (AB-286-NA)(8)

Publications using AB-286-NA

• Qimei Gong, Junyu Zeng, Xufang Zhang, Yihua Huang, Chanchan Chen, Jingjing Quan et al. Effect of erythropoietin on angiogenic potential of dental pulp cells Experimental and Therapeutic Medicine 7/28/2021 [PMID: 34447472]
• Qimei Gong, Junyu Zeng, Xufang Zhang, Yihua Huang, Chanchan Chen, Jingjing Quan et al. Effect of erythropoietin on angiogenic potential of dental pulp cells Experimental and Therapeutic Medicine 2021-07-28 [PMID: 34447472] (Neutralization, Human)
• T Susantad, M Fuangthong, K Tharakaram, P Tit-Oon, M Ruchirawat, R Sasisekhar Modified recombinant human erythropoietin with potentially reduced immunogenicity Scientific Reports, 2021-01-15;11(1):1491. 2021-01-15 [PMID: 33452310] (ELISA Detection, Western Blot, Human)
• A Costello, NT Lao, N Barron, M Clynes Continuous Translation of Circularized mRNA Improves Recombinant Protein Titer Metab. Eng., 2019-01-04;0(0):. 2019-01-04 [PMID: 30615942] (Western Blot, Transgenic Hamster)
• Spitzbarth I, Lempp C, Kegler K et al. Immunohistochemical and transcriptome analyses indicate complex breakdown of axonal transport mechanisms in canine distemper leukoencephalitis. Brain Behav. 5/3/2016 [PMID: 27247850]
• Stefan Kol, Thomas Beuchert Kallehauge, Simon Adema, Pim Hermans Development of a VHH-Based Erythropoietin Quantification Assay Molecular Biotechnology 8/1/2015 [PMID: 25764454]
• Jakub Jez, Alexandra Castilho, Josephine Grass, Karola Vorauer‐Uhl, Thomas Sterovsky, Friedrich Altmann et al. Expression of functionally active sialylated human erythropoietin in plants Biotechnology Journal 3/1/2013 [PMID: 23325672]
• Hwang DS, Gim Y, Yoo HJ, Cha HJ Practical recombinant hybrid mussel bioadhesive fp-151. Biomaterials, 2007-05-03;28(24):3560-8. 2007-05-03 [PMID: 17507090] (ICC, Human)

Review for Erythropoietin/EPO Antibody (AB-286-NA) (1)

Average Rating: 4

(Based on 1 review)

We have 1 review tested in 1 species: Other.

reviewed by: Verified Customer WB Other 01/05/2015

Summary

• Application: Western Blot
• Sample Tested: See PMID 19127370
• Species: Other

Bioinformatics

• Gene Symbol: EPO